Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity. In Vitro Caracemide inactivates R1 by covalent modification at the substrate-binding site and has a toxic metabolite, methylisocyanate (MIC), in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The mercapturic acid derivative AMCC was identified in urine rats following administration to rats of a single i.p. dose (6.6 mg/kg) of caracemide (NSC-253272) . . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Caracemide
CAS number：81424-67-1 molecular formula：C6H11N3O4
overview
compound introduction
Specs
| Chinese alias | 卡拉西酰胺 | ||
| English alias | - | ||
| CAS number | 81424-67-1 | molecular formula | C6H11N3O4 |
| molecular weight | 189.17 g/mol | Exact mass | ≥95% |
| PSA | 87.700 Ų | logp | -0.200 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
